MyFinsight
Home
Blog
About
Contact
Download
Download image
Proceeds from the march
2026 public...
$79,636,964
Proceeds from the march
2026 public offering...
$7,238,000
Proceeds from exercised
warrants
$2,975,000
Proceeds from exercise of
stock options
$113,116
Net cash provided by
(used in) financing...
$89,921,121
Effect of exchange rate
changes on cash and cash...
$14,729
Canceled cashflow
$41,959
Net increase
(decrease) in cash and cash...
$10,017,044
Canceled cashflow
$79,918,806
Principal payments on
finance leases
$37,388
Tax payments for
share settlement of...
$4,571
Proceeds from sales and
maturities of investments
$74,596,145
Proceeds from the sale of
equipment
$2,217
Stock-based compensation
expense
$5,459,911
Depreciation and
amortization
$730,965
Changes in fair value of
warrant liabilities
$482,474
Accounts payable
$114,119
Amortization of finance
right-of-use assets
$21,705
Accretion of discounts on
investments
-$10,075
Net realized and
unrealized (gain) loss on...
-$9,587
Net cash provided by
(used in) investing...
-$65,647,676
Net cash used in
operating activities
-$14,271,130
Canceled cashflow
$74,598,362
Canceled cashflow
$6,828,836
Purchases of investments
$139,262,781
Net loss
-$18,868,885
Purchases of equipment
$983,257
Accrued expense and
other current...
-$1,194,966
Accrued interest
receivable
$608,280
Prepaid expenses and
other current assets
$297,263
Operating lease
right-of-use assets and...
$74,224
Net realized gain on
debt securities
$47,089
Gain in early
termination of lease...
$7,042
Gain on the sale of
equipment
$2,217
Back
Back
Cash Flow
SAB Biotherapeutics, Inc. (SABS)
SAB Biotherapeutics, Inc. (SABS)
source: myfinsight.com